NEW YORK (GenomeWeb News) – Canada's Centre for Drug Research and Development and the Pan Alberta Metabolomics Platform today announced the signing of a preferred collaboration agreement covering projects of mutual interest.
"This agreement is the starting point for both organizations to leverage each other's expertise and infrastructure: PANAMP's platform complementing CDRD's mandate to translated academic research into important therapeutics," said Karimah Es Sabar, senior vice president of business and strategic affairs for CDRD, in a statement.
Financial and other terms of the deal were not disclosed.
PANAMP calls itself a "distributed" core facility with expertise in metabolomic studies for clinical trials, biomedical studies, bioproduct studies, nutrient profiling, and environmental testing. It has access to more than C$5 million ($5.1 million) in state-of-the-art metabolomics infrastructure situated at the University of Alberta and the University of Calgary.
Supported by lab managers, NMR spectroscopists, mass spectrometrists, chemists, computer scientists, statisticians, and bioinformaticians, PANAMP can identify and quantify up to 2,000 different chemicals from certain biological samples, five times more comprehensive than other services currently available, CDRD said.
CDRD has a suite of drug development equipment and more than 20,000 square feet of lab space on the campuses of the University of British Columbia, Simon Fraser University, and the BC Cancer Agency.